Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamel Laribi

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Blood Advances|December 8, 2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA groupRaphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, et al.
Blood Advances|November 29, 2021
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemiaCristina Bagacean, Rémi Letestu, Chadi Al-Nawakil, et al.
Annals of Hematology|January 26, 2021
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohortFlorian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, et al.
Haematologica|May 28, 2026
Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa studyJulien Lazarovici, Sandy Amorim, Krimo Bouabdallah, et al.
The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.
Cancer|April 15, 2026
Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world studyArthur Coste, Nanthara Sritharan, Anne Lok, et al.
British Journal of Haematology|June 21, 2021
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life studyThibault Comont, Mathieu Meunier, Amina Cherait, et al.
Leukemia & Lymphoma|July 4, 2015
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemiaCaroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al.
Haematologica|February 25, 2021
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemiaVincent Jachiet, Guillaume Moulis, Jérome Hadjadj, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Blood Advances|December 8, 2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA groupRaphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, et al.
Blood Advances|November 29, 2021
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemiaCristina Bagacean, Rémi Letestu, Chadi Al-Nawakil, et al.
Annals of Hematology|January 26, 2021
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohortFlorian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, et al.
Haematologica|May 28, 2026
Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa studyJulien Lazarovici, Sandy Amorim, Krimo Bouabdallah, et al.
The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.
Cancer|April 15, 2026
Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world studyArthur Coste, Nanthara Sritharan, Anne Lok, et al.
British Journal of Haematology|June 21, 2021
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life studyThibault Comont, Mathieu Meunier, Amina Cherait, et al.
Leukemia & Lymphoma|July 4, 2015
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemiaCaroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al.
Haematologica|February 25, 2021
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemiaVincent Jachiet, Guillaume Moulis, Jérome Hadjadj, et al.
Pageof 11